Financhill
Sell
44

BNTX Quote, Financials, Valuation and Earnings

Last price:
$98.60
Seasonality move :
18.7%
Day range:
$96.38 - $98.88
52-week range:
$76.53 - $131.49
Dividend yield:
0%
P/E ratio:
191.55x
P/S ratio:
8.00x
P/B ratio:
1.16x
Volume:
598.5K
Avg. volume:
1.3M
1-year change:
-0.32%
Market cap:
$23.7B
Revenue:
$3B
EPS (TTM):
-$3.40

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
BNTX
BioNTech SE
$183.4M -$2.66 17.83% -19.71% $131.77
AZN
AstraZeneca PLC
$13.7B $1.12 8.72% 84.16% $84.60
DBVT
DBV Technologies SA
$501.4K -$0.24 -- -87.99% $18.41
MRNA
Moderna
$115.3M -$3.11 -49.84% -11.55% $47.70
NCNA
NuCana PLC
-- -$0.01 -- -99.69% $104.00
NVAX
Novavax
$343.9M $1.41 -64.18% -84.85% $14.67
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
BNTX
BioNTech SE
$98.68 $131.77 $23.7B 191.55x $0.00 0% 8.00x
AZN
AstraZeneca PLC
$70.41 $84.60 $218.3B 28.28x $1.05 2.2% 4.00x
DBVT
DBV Technologies SA
$8.41 $18.41 $230M -- $0.00 0% --
MRNA
Moderna
$26.26 $47.70 $10.2B -- $0.00 0% 3.25x
NCNA
NuCana PLC
$0.04 $104.00 $230.2K -- $0.00 0% --
NVAX
Novavax
$7.25 $14.67 $1.2B 2.74x $0.00 0% 0.99x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
BNTX
BioNTech SE
1.53% 1.910 1.45% 9.86x
AZN
AstraZeneca PLC
42.02% 0.321 13.05% 0.69x
DBVT
DBV Technologies SA
-- -3.919 -- --
MRNA
Moderna
-- 0.406 -- 3.92x
NCNA
NuCana PLC
-- -0.390 -- --
NVAX
Novavax
180.06% 9.436 16.39% 1.84x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
BNTX
BioNTech SE
$104.2M -$562M -3.86% -3.91% -225.11% -$1.5B
AZN
AstraZeneca PLC
$11.3B $3.7B 10.93% 19.55% 27.61% $2.7B
DBVT
DBV Technologies SA
-- -$26.6M -- -- -- -$19.7M
MRNA
Moderna
$17M -$1.1B -29.23% -29.23% -900% -$1.2B
NCNA
NuCana PLC
-- -$1.6M -- -- -- -$9.3M
NVAX
Novavax
$612.2M $515.5M -- -- 83.91% -$187.1M

BioNTech SE vs. Competitors

  • Which has Higher Returns BNTX or AZN?

    AstraZeneca PLC has a net margin of -227.46% compared to BioNTech SE's net margin of 21.46%. BioNTech SE's return on equity of -3.91% beat AstraZeneca PLC's return on equity of 19.55%.

    Company Gross Margin Earnings Per Share Invested Capital
    BNTX
    BioNTech SE
    54.16% -$1.82 $20.8B
    AZN
    AstraZeneca PLC
    83.51% $0.94 $70.9B
  • What do Analysts Say About BNTX or AZN?

    BioNTech SE has a consensus price target of $131.77, signalling upside risk potential of 33.53%. On the other hand AstraZeneca PLC has an analysts' consensus of $84.60 which suggests that it could grow by 20.15%. Given that BioNTech SE has higher upside potential than AstraZeneca PLC, analysts believe BioNTech SE is more attractive than AstraZeneca PLC.

    Company Buy Ratings Hold Ratings Sell Ratings
    BNTX
    BioNTech SE
    14 4 0
    AZN
    AstraZeneca PLC
    6 1 0
  • Is BNTX or AZN More Risky?

    BioNTech SE has a beta of 1.347, which suggesting that the stock is 34.675% more volatile than S&P 500. In comparison AstraZeneca PLC has a beta of 0.396, suggesting its less volatile than the S&P 500 by 60.428%.

  • Which is a Better Dividend Stock BNTX or AZN?

    BioNTech SE has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AstraZeneca PLC offers a yield of 2.2% to investors and pays a quarterly dividend of $1.05 per share. BioNTech SE pays -- of its earnings as a dividend. AstraZeneca PLC pays out 65.8% of its earnings as a dividend. AstraZeneca PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios BNTX or AZN?

    BioNTech SE quarterly revenues are $192.3M, which are smaller than AstraZeneca PLC quarterly revenues of $13.6B. BioNTech SE's net income of -$437.5M is lower than AstraZeneca PLC's net income of $2.9B. Notably, BioNTech SE's price-to-earnings ratio is 191.55x while AstraZeneca PLC's PE ratio is 28.28x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioNTech SE is 8.00x versus 4.00x for AstraZeneca PLC. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BNTX
    BioNTech SE
    8.00x 191.55x $192.3M -$437.5M
    AZN
    AstraZeneca PLC
    4.00x 28.28x $13.6B $2.9B
  • Which has Higher Returns BNTX or DBVT?

    DBV Technologies SA has a net margin of -227.46% compared to BioNTech SE's net margin of --. BioNTech SE's return on equity of -3.91% beat DBV Technologies SA's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    BNTX
    BioNTech SE
    54.16% -$1.82 $20.8B
    DBVT
    DBV Technologies SA
    -- -$1.30 --
  • What do Analysts Say About BNTX or DBVT?

    BioNTech SE has a consensus price target of $131.77, signalling upside risk potential of 33.53%. On the other hand DBV Technologies SA has an analysts' consensus of $18.41 which suggests that it could grow by 118.9%. Given that DBV Technologies SA has higher upside potential than BioNTech SE, analysts believe DBV Technologies SA is more attractive than BioNTech SE.

    Company Buy Ratings Hold Ratings Sell Ratings
    BNTX
    BioNTech SE
    14 4 0
    DBVT
    DBV Technologies SA
    0 0 0
  • Is BNTX or DBVT More Risky?

    BioNTech SE has a beta of 1.347, which suggesting that the stock is 34.675% more volatile than S&P 500. In comparison DBV Technologies SA has a beta of -0.661, suggesting its less volatile than the S&P 500 by 166.125%.

  • Which is a Better Dividend Stock BNTX or DBVT?

    BioNTech SE has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioNTech SE pays -- of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BNTX or DBVT?

    BioNTech SE quarterly revenues are $192.3M, which are larger than DBV Technologies SA quarterly revenues of --. BioNTech SE's net income of -$437.5M is lower than DBV Technologies SA's net income of -$27.1M. Notably, BioNTech SE's price-to-earnings ratio is 191.55x while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioNTech SE is 8.00x versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BNTX
    BioNTech SE
    8.00x 191.55x $192.3M -$437.5M
    DBVT
    DBV Technologies SA
    -- -- -- -$27.1M
  • Which has Higher Returns BNTX or MRNA?

    Moderna has a net margin of -227.46% compared to BioNTech SE's net margin of -907.48%. BioNTech SE's return on equity of -3.91% beat Moderna's return on equity of -29.23%.

    Company Gross Margin Earnings Per Share Invested Capital
    BNTX
    BioNTech SE
    54.16% -$1.82 $20.8B
    MRNA
    Moderna
    15.89% -$2.52 $10.1B
  • What do Analysts Say About BNTX or MRNA?

    BioNTech SE has a consensus price target of $131.77, signalling upside risk potential of 33.53%. On the other hand Moderna has an analysts' consensus of $47.70 which suggests that it could grow by 81.63%. Given that Moderna has higher upside potential than BioNTech SE, analysts believe Moderna is more attractive than BioNTech SE.

    Company Buy Ratings Hold Ratings Sell Ratings
    BNTX
    BioNTech SE
    14 4 0
    MRNA
    Moderna
    5 17 1
  • Is BNTX or MRNA More Risky?

    BioNTech SE has a beta of 1.347, which suggesting that the stock is 34.675% more volatile than S&P 500. In comparison Moderna has a beta of 1.995, suggesting its more volatile than the S&P 500 by 99.542%.

  • Which is a Better Dividend Stock BNTX or MRNA?

    BioNTech SE has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioNTech SE pays -- of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BNTX or MRNA?

    BioNTech SE quarterly revenues are $192.3M, which are larger than Moderna quarterly revenues of $107M. BioNTech SE's net income of -$437.5M is higher than Moderna's net income of -$971M. Notably, BioNTech SE's price-to-earnings ratio is 191.55x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioNTech SE is 8.00x versus 3.25x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BNTX
    BioNTech SE
    8.00x 191.55x $192.3M -$437.5M
    MRNA
    Moderna
    3.25x -- $107M -$971M
  • Which has Higher Returns BNTX or NCNA?

    NuCana PLC has a net margin of -227.46% compared to BioNTech SE's net margin of --. BioNTech SE's return on equity of -3.91% beat NuCana PLC's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    BNTX
    BioNTech SE
    54.16% -$1.82 $20.8B
    NCNA
    NuCana PLC
    -- -$0.32 --
  • What do Analysts Say About BNTX or NCNA?

    BioNTech SE has a consensus price target of $131.77, signalling upside risk potential of 33.53%. On the other hand NuCana PLC has an analysts' consensus of $104.00 which suggests that it could grow by 273584.21%. Given that NuCana PLC has higher upside potential than BioNTech SE, analysts believe NuCana PLC is more attractive than BioNTech SE.

    Company Buy Ratings Hold Ratings Sell Ratings
    BNTX
    BioNTech SE
    14 4 0
    NCNA
    NuCana PLC
    0 1 0
  • Is BNTX or NCNA More Risky?

    BioNTech SE has a beta of 1.347, which suggesting that the stock is 34.675% more volatile than S&P 500. In comparison NuCana PLC has a beta of 1.639, suggesting its more volatile than the S&P 500 by 63.921%.

  • Which is a Better Dividend Stock BNTX or NCNA?

    BioNTech SE has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NuCana PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioNTech SE pays -- of its earnings as a dividend. NuCana PLC pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BNTX or NCNA?

    BioNTech SE quarterly revenues are $192.3M, which are larger than NuCana PLC quarterly revenues of --. BioNTech SE's net income of -$437.5M is lower than NuCana PLC's net income of -$836.1K. Notably, BioNTech SE's price-to-earnings ratio is 191.55x while NuCana PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioNTech SE is 8.00x versus -- for NuCana PLC. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BNTX
    BioNTech SE
    8.00x 191.55x $192.3M -$437.5M
    NCNA
    NuCana PLC
    -- -- -- -$836.1K
  • Which has Higher Returns BNTX or NVAX?

    Novavax has a net margin of -227.46% compared to BioNTech SE's net margin of 82.81%. BioNTech SE's return on equity of -3.91% beat Novavax's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    BNTX
    BioNTech SE
    54.16% -$1.82 $20.8B
    NVAX
    Novavax
    97.75% $2.93 $94.5M
  • What do Analysts Say About BNTX or NVAX?

    BioNTech SE has a consensus price target of $131.77, signalling upside risk potential of 33.53%. On the other hand Novavax has an analysts' consensus of $14.67 which suggests that it could grow by 102.3%. Given that Novavax has higher upside potential than BioNTech SE, analysts believe Novavax is more attractive than BioNTech SE.

    Company Buy Ratings Hold Ratings Sell Ratings
    BNTX
    BioNTech SE
    14 4 0
    NVAX
    Novavax
    3 2 0
  • Is BNTX or NVAX More Risky?

    BioNTech SE has a beta of 1.347, which suggesting that the stock is 34.675% more volatile than S&P 500. In comparison Novavax has a beta of 3.210, suggesting its more volatile than the S&P 500 by 220.956%.

  • Which is a Better Dividend Stock BNTX or NVAX?

    BioNTech SE has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Novavax offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioNTech SE pays -- of its earnings as a dividend. Novavax pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BNTX or NVAX?

    BioNTech SE quarterly revenues are $192.3M, which are smaller than Novavax quarterly revenues of $626.3M. BioNTech SE's net income of -$437.5M is lower than Novavax's net income of $518.6M. Notably, BioNTech SE's price-to-earnings ratio is 191.55x while Novavax's PE ratio is 2.74x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioNTech SE is 8.00x versus 0.99x for Novavax. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BNTX
    BioNTech SE
    8.00x 191.55x $192.3M -$437.5M
    NVAX
    Novavax
    0.99x 2.74x $626.3M $518.6M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Where Will Palo Alto Networks Stock Be in 5 Years?
Where Will Palo Alto Networks Stock Be in 5 Years?

You know those companies that just refuse to slow down…

UPS Stock Forecast: Is the 6.9% Dividend Too Good to Be True?
UPS Stock Forecast: Is the 6.9% Dividend Too Good to Be True?

Parcel delivery giant UPS (NYSE:UPS) has seen its fair share…

Where Will Coinbase Stock Be in 5 Years?
Where Will Coinbase Stock Be in 5 Years?

If you’ve been anywhere near the crypto world over the…

Stock Ideas

Buy
65
Is MSFT Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 38x

Buy
65
Is NVDA Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 45x

Sell
33
Is AAPL Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 32x

Alerts

Buy
55
SBET alert for May 27

SharpLink Gaming [SBET] is up 454.46% over the past day.

Buy
57
RGC alert for May 27

Regencell Bioscience Holdings [RGC] is down 9.77% over the past day.

Buy
90
OKLO alert for May 27

Oklo [OKLO] is up 10.05% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock